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Editorial: you bet your life – medication risk taking by
gastroparesis patients in a hypothetical exercise
Two thirds of gastroparesis patients rate their health as fair to poor
or are dissatisfied with available treatments, reflecting impaired qual-
ity of life (QOL).1 Generic surveys (eg SF‐36) quantify impact of
health status on physical and mental activities and permit QOL com-
parisons with other disorders.2 Disease‐specific questionnaires (eg
PAGI‐QOL) query effects of food on functioning possibly offering
more sensitive detection of reduced QOL.2
Such observations do not describe sacrifices patients make for
better health. Risk taking is another component of QOL. Clinicians
already know gastroparesis patients take risks when choosing thera-
pies with possible irreversible or fatal consequences (eg metoclo-
pramide, domperidone, gastric surgeries). Navas et al employed
standard gamble methodology to quantify gastroparesis patients’
acceptance of medication risks.3 One hundred and three patients
with moderate to severe symptoms stated they would accept a
13.4% risk of immediate death to ensure cure of gastroparesis with
one dose of a hypothetical drug. Those with severe symptoms or
psychosocial dysfunction were willing to assume greater risks.
Nearly half expressed hopelessness their symptoms would ever
resolve.
The standard gamble was described in 1953 to define the risk
of death a person would accept to achieve perfect health when
offered curative therapy.4 Standard gambles define a value called
utility that ranges from 0 (dead) to 1.0 (perfect health) (Figure 1).
Conditions with bleak outcomes have lower utilities while chronic
illnesses with little mortality risk score higher. In this study, willing-
ness to accept a 13.4% mortality risk translates into a utility of
0.866 (1−0.134). Functional dyspepsia patients assume a similar
12.7% possibility of death—an expected finding given the overlap
of functional dyspepsia with gastroparesis and the lack of impact
of gastric emptying delays on QOL in diabetics with dyspeptic
symptoms.5,6 However, IBS patients accept a 1% mortality risk for
immediate cure suggesting lesser QOL impairments than gastro-
paresis.7
Quantitative findings of standard gambles should not be overin-
terpreted. Binary standard gamble choices rarely mimic standard
management options offered in clinical practice.8 No medication
cures gastroparesis in one dose and mortality from gastroparesis
unrelated to comorbid illness is rare. Thus, absolute risk percentages
based on artificial premises of this standard gamble might not reflect
accurate risk considerations when traditional treatments are advo-
cated. Study design factors known to influence standard gamble util-
ity include changing risk wording from death to survival and
modifying ordering of the survey mortality probabilities from a
sequential profile as in this study to a “ping pong” pattern where
risks of death from 0% to 100% are ordered randomly.9,10
These limitations do not diminish the importance of this study or
conclusions of the willingness of gastroparesis patients to consider
risks when making treatment decisions. These findings complement
the emerging literature on QOL deficits in gastroparesis. One hopes
STANDARD GAMBLE




Excellent health for rest of life
F IGURE 1 The standard gamble for the study 3 in gastroparesis is shown. A patient is offered a choice between alternative 1 (living the
rest of his/her life with chronic stable gastroparesis symptoms) or alternative 2 (accepting a risk of “gambling” between excellent health for the
rest of his/her life vs immediate death). The probability of excellent health (P) is varied until the patient is indifferent between the chronic
gastroparesis health state and the gamble. Figure adapted from Reference 2
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that future studies will contrast standard gamble findings concur-
rently with other functional and motility disorders to clarify the extra
illness burden assumed in gastroparesis and correlate standard gam-
ble utilities with other QOL surveys to inform caregivers when con-
sidering treatments for refractory symptoms.
ACKNOWLEDGEMENTS
Declaration of personal interests: None.
ORCID
William L. Hasler https://orcid.org/0000-0002-6158-2871
L INKED CONTENT
This article is linked to Navas et al paper. To view this article, visit
https://doi.org/10.1111/apt.15112.
William L. Hasler
University of Michigan Health System, Ann Arbor, Michigan
Email: whasler@umich.edu
REFERENCES
1. Yu D, Ramsey FV, Norton WF, et al. The burdens, concerns, and qual-
ity of life of patients with gastroparesis. Dig Dis Sci. 2017;62:829‐
893.
2. Eisen GM, Locke GR, Provenzale D. Health‐related quality of life: a
primer for gastroenterologists. Am J Gastroenterol. 1999;94:2017‐
2021.
3. Navas CM, Crowell MD, Lacy BE. The willingness of patients with
gastroparesis to take risks with medications. Aliment Pharmacol Ther
2019;49:429‐436.
4. Von Neumann J, Morgenstern D. The theory of games and economic
behavior, 3rd ed. New York, NY: John Wiley; 1953.
5. Lacy BE, Yu J, Crowell MD. Medication risk‐taking behavior in func-
tional dyspepsia patients. Clin Transl Gastroenterol. 2015;6:e69.
6. Teigland T, Iversen MM, Sangnes DA, Dimcevski G, Softeland E. A
longitudinal study on patients with diabetes and symptoms of gas-
troparesis—associations with impaired quality of life and increased
depressive and anxiety symptoms. J Diabetes Complications.
2018;32:89‐94.
7. Lacy BE, Everhart KK, Weiser KT, et al. IBS patients’ willingness to
take risks with medications. Am J Gastroenterol. 2012;107:804‐809.
8. Kaplan RM, Feeny D, Revicki DA. Methods for assessing relative
importance in preference based outcome measures. Qual Life Res.
1993;2:467‐475.
9. Slovic P. Perception of risk. Science. 1987;236:280‐285.
10. Lenert LA, Cher DJ, Goldstein MK, Bergen MR, Garber A. The effect
of search procedures on utility elicitations. Med Decis Making.
1998;18:76‐83.
DOI: 10.1111/apt.15194
Editorial: should we abandon HCV genotype testing? Maybe
Hepatitis C virus (HCV) genotype testing has been one of the main-
stays of HCV management since the 1990s as it was the strongest
predictor of treatment outcome with Interferon‐based regimens, and
was associated with the velocity of progression to cirrhosis if left
untreated.1,2 Its role was not diminished by the introduction of
directly acting anti‐virals (DAAs) as first‐ and second‐generation
DAAs were genotype specific in their activity and had different
treatment schedules based on HCV genotype and subtype.3 The
availability of pan‐genotypic DAA combinations however, calls for an
evaluation of the need for HCV genotype testing before treatment
initiation. The recent EASL guidelines eliminate HCV genotype test-
ing only in the setting of resource‐limited countries where a simpli-
fied treatment algorithm could increase access to treatment and
favor HCV elimination.4 Whether this recommendation should be
extended to all treatment settings is still a matter of debate. In this
scenario, the study by Mettikanont et al5 is of relevance as it is the
first systematic review to address the epidemiology and treatment
options for genotype 6 infections. Genotype 6 (GT6) chronic hepati-
tis C virus infection accounts for less than 5% of the global preva-
lence of HCV and is particularly rare in western countries. However,
it is responsible for a significant proportion of HCV infections in Asia
where among the 1 000 000 HCV‐infected patients, genotype 6 has
a prevalence of 20%‐50% in South‐East Asia and Southern China
respectively.6 When looking at the efficacy of the pan‐genotypic
combinations of sofobuvir/velpatasvir (SOF/VEL) and glecaprevir/pi-
brentasvir (G/P), the SVR rates were 100% (135/135) and 99% (107/
108) respectively. However, the efficacy was lower when analysing
SVR rates obtained with sofosbuvir/ledipasvir (SOF/LDV), as a 64%
SVR rate (25/39) was reported in a study conducted in Myanmar.
Interestingly, the majority of the patients treated in Myanmar were
infected by GT6c‐i subtypes, whereas patients participating in stud-
ies conducted in other countries, where SVR rates to SOF/LDV
reached the 95% rate, were infected mainly by GT6a.7,8 Whether
this finding is the consequence of the reduced activity of SOF/LDV
in HCV‐6, or on the other hand highlights a difficult to cure strain in
HCV GT6c‐I still needs to be elucidated. Similarly, a recent study by
Fourati et al analysing HCV DAA failures in France, identified GT4r
as a predictor of treatment failure due to frequent preexistence of
both NS5A and NS5B S282 RASs. However, once again all but one
of the analysed patients had failed SOF/LDV, making it impossible to
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